

### 4.0.3 DOC Cmte minutes

## Dementia Guideline Committee meeting 9 – development

**Date:** 08/09/2016

**Location:** NICE offices, Manchester

**Minutes:** Final



<b>Committee members present:</b>	
John O'Brien (JO) (chair)	Present for all
Louise Allan (LA)	Present for all
Kevin Minier (KMin)	Present for all
Ruth O'Dea (RO)	Present for all
Jeremy Isaacs (JI)	Present for all
Linda Clare (LC)	Present for all
Hannah Luff (HL)	Present from item 3
Karen Harrison-Denning (KHD)	Present for all
Louise Robinson (LR)	Present for all
Tracey Wright (TW)	Present for all
Sarah Partington (SP)	Present for all
Richard Clibbens (RC)	Present for all
Sandra Evans (SE)	Present for all

<b>In attendance:</b>		
Vicky Gillis (VG)	ICG – Technical Analyst	Present for all
Gabriel Rogers (GR)	ICG – Health Economic Advisor	Present for all
Joshua Pink (JP)	ICG – Technical Advisor	Present for all
Rupert Franklin (RF)	NICE – Commissioning programme manager	Present for all
Angela Parkin (AP)	NICE Medicines Advisor	Present for all
Elizabeth Barrett (EB)	NICE Information Specialist	Present for all
Daniel Davies (DD)	ICG - Project Manager	Present for all
Harry Allen (HA)	ICG – Expert Advisor	Present until item 7
Edgar Masanga (EM)	Business Analyst - Resource Impact Assessment	Present until item 4
Carol Paton (CP) (expert witness)	Honorary Research Fellow, Imperial College London & Joint Head, POMH-UK	Present from item 4

<b>Observers:</b>
-------------------

### 4.0.3 DOC Cmte minutes

Katherine McAllister	Technical Analyst, Internal Clinical Guidelines
----------------------	---

<b>Apologies:</b>	
Damien Longson (DL)	Committee Chair
Carol Duff (CD)	Committee member
Chris Roberts (CR)	Committee member
Paul Dunnery (PD)	Committee member
Catherine Pascoe (CP)	Co-opted member
Joanne Brady (JB)	Co-opted member
Kate Mitchell (KM)	Co-opted member
Sue Spiers (SS)	ICG – Associate Director

#### **1. Welcome, apologies, objectives for the meeting, declaration of interests and minutes of previous meeting**

The Chair welcomed the Committee members and attendees to the ninth meeting of the dementia guideline committee.

Apologies for the meeting were received as detailed above.

The Chair outlined the proposed objectives of the meeting and asked each attendee to declare any new conflicts.

Jl declared a non-personal interest due to his hospital's involvement as a principal site on the CREAD clinical trial of Crenezumab versus placebo in prodromal and mild Alzheimer's disease which is sponsored by Roche.

No other committee members declared any new interests.

It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

#### **2. Resource Impact Assessment programme presentation**

EM presented information on NICE's Resource Impact Assessment programme, and took questions from the committee.

#### **3. Review Question 27: How effective are cholinesterase inhibitors and memantine for types of dementia other than typical Alzheimer's disease?**

VG recapped the review protocol and presented the evidence supporting Review Question 27 for the committee's consideration.

Following the presentation the committee discussed the evidence and drafted three

### 4.0.3 DOC Cmte minutes

recommendations.
<b>4. Health economic plan update</b>
JE presented an update on the progress of the health economic plan and took questions from the committee.
<b>5. Presentation from the Prescribing Observatory for Mental Health (POMH)</b>
CP presented findings from the POMH Quality Improvement Programmes regarding prescribing for people with dementia. CP presented the findings as an expert witness for the committee and invited questions from the committee on what had been provided.
<b>6. Review Question 18: What drugs may worsen cognitive decline in people diagnosed with dementia?</b>
Following the expert witness presentation, the committee discussed the evidence and drafted two recommendations for review question 18.
<b>7. Any other business</b>
JP provided an update on the topics for discussion at the next meeting.  The committee discussed the circulation of the guideline schedule. JP requested that any further comments be received by 12.00 Tuesday 13 September.

**Date of next meeting:** Tuesday 18 October 2016

**Location of next meeting:** NICE offices, Manchester